But like you said, with the $35 a month cap on insulin drugs, that again was only supposed to apply to Medicare. But what we have witnessed is that Insulin manufacturers have now extended that price cap across the board to non Medicare recipients. So that's really the intent of it because it's really hard to charge one price to one group of people and another price to another group of people. (10:59–11:07)
CLAIM
Asserts that insulin manufacturers have extended the $35 price cap to non-Medicare recipients.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
